Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital

Core Viewpoint - OSE Immunotherapeutics SA has corrected a processing error regarding the total number of shares and voting rights, which was identified in preparation for the upcoming General Meeting on September 30, 2025. The error does not affect the rights of beneficiaries or previously cast votes [2][3][4]. Group 1: Correction of Material Error - The total number of outstanding shares is now confirmed to be 22,463,262, with theoretical voting rights amounting to 27,859,524 [3]. - The error was due to an inaccurate legal qualification by a corporate advisor and was promptly addressed by the Board of Directors on September 23, 2025 [4]. Group 2: Response to Allegations - OSE Immunotherapeutics refutes allegations of "fraudulent manipulation" made by a group of minority shareholders, asserting that the error was unintentional and not a result of deliberate actions [4][5]. - The company expresses regret over the aggressive communication strategy adopted by certain minority shareholders, emphasizing its commitment to constructive dialogue with all shareholders [5]. Group 3: Shareholder Agreement and Voting Intentions - A group of 61 founding, historical, employee, and executive shareholders has entered into an agreement regarding the voting of resolutions at the General Meeting [6]. - This Shareholder Group now holds approximately 14.22% of the company's share capital and 19.05% of voting rights, and they intend to vote in favor of the Board of Directors' proposed resolutions while opposing those from the minority shareholders [7]. Group 4: Proxy Advisory Recommendations - Two international proxy advisory firms have recommended voting in favor of the resolutions proposed by the Board of Directors concerning its composition [8]. - The firms have differing opinions on other resolutions related to executive remuneration and financial authorizations, encouraging shareholders to review the full recommendations [9].